Secondary Hyperparathyroidism- latest pipeline guide, Development by Phase and Review 2019

Albany, US, 2019-Sep-30 — /EPR Network/ —Market Research Hub (MRH) has recently uploaded a new study titled “Secondary Hyperparathyroidism-Pipeline Review, H2 2019” to its broad online storehouse. The global Secondary Hyperparathyroidism conveniently covers prime factors motivating development and steering industry trends and demand scenarios. Readers can easily quantify market opportunities with the availability of information such as market sizing and market forecasting, thereby being able to analyze the prevailing status across the global Secondary Hyperparathyroidism.

Get Sample Copy at https://www.marketresearchhub.com/enquiry.php?type=S&repid=2519470

Secondary Hyperparathyroidism – Pipeline Review, H2 2019

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Secondary Hyperparathyroidism – Pipeline Review, H2 2019, provides an overview of the Secondary Hyperparathyroidism (Hormonal Disorders) pipeline landscape.

Secondary hyperparathyroidism is occurs when the parathyroid glands in neck produce too much parathyroid hormone (PTH) because calcium levels are too low. Symptoms include bone deformities, broken bones, swollen joints and chronic kidney failure. Treatment includes calcimimetic and hormone replacement therapy.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Secondary Hyperparathyroidism – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Secondary Hyperparathyroidism (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Secondary Hyperparathyroidism (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Secondary Hyperparathyroidism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 1, 3 and 2 respectively.

Secondary Hyperparathyroidism (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Secondary Hyperparathyroidism (Hormonal Disorders).
– The pipeline guide reviews pipeline therapeutics for Secondary Hyperparathyroidism (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Secondary Hyperparathyroidism (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Secondary Hyperparathyroidism (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Secondary Hyperparathyroidism (Hormonal Disorders)

Browse Complete Report at https://www.marketresearchhub.com/report/secondary-hyperparathyroidism-pipeline-review-h2-2019-report.html

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Secondary Hyperparathyroidism – Overview
Secondary Hyperparathyroidism – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Secondary Hyperparathyroidism – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Secondary Hyperparathyroidism – Companies Involved in Therapeutics Development
Amgen Inc
EA Pharma Co Ltd
Lupin Ltd
Mitsubishi Tanabe Pharma Corp
OPKO Health Inc
Secondary Hyperparathyroidism – Drug Profiles
AJT-240 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
calcifediol ER – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cinacalcet – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CK-15 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTA-091 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Dendocrin – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etelcalcetide hydrochloride – Drug Profile
Product Description
Mechanism Of Action
R&D Progress

Make an Enquiry about This Report https://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=2519470

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports of different sector like Pharmaceuticals market research   and analysis. MRH’s expansive collection of industry reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Us

90 State Street,

Albany, NY 12207,

United States

Toll Free: 800-998-4852 (US-Canada)

Email: press@marketresearchhub.com

Website: http://www.marketresearchhub.com/

Read Industry News at: https://www.industrynewsanalysis.com/

 

Matched content

Editor’s pick

Express Press Release Distribution